- Home
- EQBK vs MYGN Comparison
EQBK vs MYGN Comparison
Compare EQBK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- MYGN
- Stock Information
- Founded
- EQBK 2002
- MYGN 1991
- Country
- EQBK United States
- MYGN United States
- Employees
- EQBK N/A
- MYGN N/A
- Industry
- EQBK Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EQBK Finance
- MYGN Health Care
- Exchange
- EQBK Nasdaq
- MYGN Nasdaq
- Market Cap
- EQBK 673.9M
- MYGN 744.7M
- IPO Year
- EQBK 2015
- MYGN 1995
- Fundamental
- Price
- EQBK $38.86
- MYGN $4.19
- Analyst Decision
- EQBK Hold
- MYGN Hold
- Analyst Count
- EQBK 6
- MYGN 16
- Target Price
- EQBK $44.20
- MYGN $15.47
- AVG Volume (30 Days)
- EQBK 43.1K
- MYGN 3.3M
- Earning Date
- EQBK 07-15-2025
- MYGN 05-06-2025
- Dividend Yield
- EQBK 1.54%
- MYGN N/A
- EPS Growth
- EQBK 543.37
- MYGN N/A
- EPS
- EQBK 3.93
- MYGN N/A
- Revenue
- EQBK $224,743,000.00
- MYGN $831,300,000.00
- Revenue This Year
- EQBK $20.11
- MYGN N/A
- Revenue Next Year
- EQBK $10.81
- MYGN $6.42
- P/E Ratio
- EQBK $9.90
- MYGN N/A
- Revenue Growth
- EQBK 56.39
- MYGN 7.38
- 52 Week Low
- EQBK $32.24
- MYGN $3.81
- 52 Week High
- EQBK $50.85
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- EQBK 46.14
- MYGN 33.61
- Support Level
- EQBK $38.59
- MYGN $3.86
- Resistance Level
- EQBK $39.49
- MYGN $4.38
- Average True Range (ATR)
- EQBK 0.68
- MYGN 0.26
- MACD
- EQBK -0.21
- MYGN 0.14
- Stochastic Oscillator
- EQBK 17.26
- MYGN 54.29
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.